TBPH
insider transactionsTheravance Biopharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-44.4K
0 buy · 44.4K sell
Net value · 365d
-$651.8K
$0 in · $651.8K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
6
0 buy · 44.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$109.1K
6.7K sh · $16.39
Own -3%
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$54.5K
3.3K sh · $16.38
Own -1%
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$54.6K
3.3K sh · $16.39
Own -1%
-
Grant·A
Director
$0
13.4K sh
Own New
-
Grant·A
Director
$0
6.0K sh
Own +8%
-
Grant·A
Director
$0
13.4K sh
Own New
-
Grant·A
Director
$0
6.0K sh
Own +10%
-
Grant·A
Director
$0
13.4K sh
Own New
-
Grant·A
Director
$0
6.0K sh
Own +8%
-
Grant·A
Director
$0
13.4K sh
Own New
-
Grant·A
Director
$0
6.0K sh
Own +14%
-
Grant·A
Director
$0
46.3K sh
Own +27%
-
Other·F
CHIEF EXECUTIVE OFFICER
$331.6K
20.0K sh · $16.55
Own -1%
-
Other·F
Aziz Sawaf KEY
SVP & CHIEF FINANCIAL OFFICER
$143.5K
8.7K sh · $16.55
Own -2%
-
Other·F
SVP, DEV & HEAD OF IRE OFFICE
$113.0K
6.8K sh · $16.55
Own -4%
-
Other·F
SVP, GEN COUNSEL AND SECRETARY
$146.1K
8.8K sh · $16.55
Own -2%
-
Other·F
SVP, COMM & MEDICAL AFFAIRS
$94.0K
5.7K sh · $16.55
Own -2%
-
Exercise·M
Director
—
7.3K sh
Own New
-
Other·F
Director
$38.0K
3.5K sh · $10.84
Own -9%
-
Exercise·M
Director
$79.2K
7.3K sh · $10.84
Own +24%
-
Grant·A
Director
—
16.7K sh
Own New
-
Grant·A
CHIEF EXECUTIVE OFFICER
$0
75.0K sh
Own +5%
-
Grant·A
Aziz Sawaf KEY
SVP & CHIEF FINANCIAL OFFICER
$0
37.5K sh
Own +12%
-
Grant·A
SVP, GEN COUNSEL AND SECRETARY
$0
37.5K sh
Own +11%
-
Grant·A
SVP, COMM & MEDICAL AFFAIRS
$0
18.8K sh
Own +8%
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$108.1K
7.8K sh · $13.92
Own -3%
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$217.5K
15.5K sh · $14.00
Own -6%
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$108.1K
7.8K sh · $13.92
Own -3%
-
Other·F
CHIEF EXECUTIVE OFFICER
$1.5M
75.0K sh · $19.66
Own -5%
-
Other·F
Aziz Sawaf KEY
SVP & CHIEF FINANCIAL OFFICER
$406.4K
20.7K sh · $19.66
Own -6%
-
Other·F
SVP, DEV & HEAD OF IRE OFFICE
$331.3K
16.9K sh · $19.66
Own -8%
-
Other·F
SVP, GEN COUNSEL AND SECRETARY
$409.6K
20.8K sh · $19.66
Own -6%
-
Other·F
SVP, COMM & MEDICAL AFFAIRS
$273.8K
13.9K sh · $19.66
Own -5%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Rhonda Farnum 10b5-1 | Sell S | 6.7K | $109.1K |
| Jun 15, 2026 | Rhonda Farnum 10b5-1 | Sell S | 3.3K | $54.5K |
| Jun 15, 2026 | Rhonda Farnum 10b5-1 | Sell S | 3.3K | $54.6K |
| Jun 12, 2026 | Alsup Laurie Smaldone | Grant A | 13.4K | $0 |
| Jun 12, 2026 | Alsup Laurie Smaldone | Grant A | 6.0K | $0 |
| Jun 12, 2026 | Deepika Pakianathan | Grant A | 13.4K | $0 |
| Jun 12, 2026 | Deepika Pakianathan | Grant A | 6.0K | $0 |
| Jun 12, 2026 | Donal O'Connor | Grant A | 13.4K | $0 |
| Jun 12, 2026 | Donal O'Connor | Grant A | 6.0K | $0 |
| Jun 12, 2026 | Susannah Gray | Grant A | 13.4K | $0 |
| Jun 12, 2026 | Susannah Gray | Grant A | 6.0K | $0 |
| May 26, 2026 | Susannah Gray | Grant A | 46.3K | $0 |
| May 20, 2026 | Rick E Winningham KEY | Other F | 20.0K | $331.6K |
| May 20, 2026 | Aziz Sawaf KEY | Other F | 8.7K | $143.5K |
| May 20, 2026 | Aine Miller | Other F | 6.8K | $113.0K |
| May 20, 2026 | Brett A. Grimaud | Other F | 8.8K | $146.1K |
| May 20, 2026 | Rhonda Farnum | Other F | 5.7K | $94.0K |
| May 14, 2026 | Donal O'Connor | Exercise M | 7.3K | — |
| May 14, 2026 | Donal O'Connor | Other F | 3.5K | $38.0K |
| May 14, 2026 | Donal O'Connor | Exercise M | 7.3K | $79.2K |
| May 13, 2026 | Donal O'Connor | Grant A | 16.7K | — |
| Apr 1, 2026 | Rick E Winningham KEY | Grant A | 75.0K | $0 |
| Apr 1, 2026 | Aziz Sawaf KEY | Grant A | 37.5K | $0 |
| Apr 1, 2026 | Brett A. Grimaud | Grant A | 37.5K | $0 |
| Apr 1, 2026 | Rhonda Farnum | Grant A | 18.8K | $0 |
| Mar 16, 2026 | Rhonda Farnum 10b5-1 | Sell S | 7.8K | $108.1K |
| Mar 16, 2026 | Rhonda Farnum 10b5-1 | Sell S | 15.5K | $217.5K |
| Mar 16, 2026 | Rhonda Farnum 10b5-1 | Sell S | 7.8K | $108.1K |
| Feb 20, 2026 | Rick E Winningham KEY | Other F | 75.0K | $1.5M |
| Feb 20, 2026 | Aziz Sawaf KEY | Other F | 20.7K | $406.4K |
| Feb 20, 2026 | Aine Miller | Other F | 16.9K | $331.3K |
| Feb 20, 2026 | Brett A. Grimaud | Other F | 20.8K | $409.6K |
| Feb 20, 2026 | Rhonda Farnum | Other F | 13.9K | $273.8K |
About TBPH insider trading
This page tracks insider transactions for Theravance Biopharma, Inc. (TBPH) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.